Pharmacokinetic and Pharmacodynamic Evaluation of Ravulizumab in Adults with Severe Coronavirus Disease 2019

media

posted on 2021-03-11, 09:33 authored by Adis journals on behalf of, Alanna C. McEneny-King, Jonathan P. R. Monteleone, Shamsah D. Kazani, Stephan R. Ortiz

Article full text

The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).

History

Usage metrics

Keywords

Antibodies Complement C5/*antagonists & inhibitors Complement Inactivating Agents/*therapeutic use Coronavirus disease 2019 Humanized/*therapeutic use Monoclonal Ravulizumab Terminal complement pathway Plain Language Summary

Licence

CC BY-NC 4.0

Pharmacokinetic and Pharmacodynamic Evaluation of Ravulizumab in Adults with Severe Coronavirus Disease 2019

History

Usage metrics

Categories

Keywords

Licence

Exports